Premium
Cyclin D1 and prognosis in human breast cancer
Author(s) -
Gillett Cheryl,
Smith Paul,
Gregory Walter,
Richards Michael,
Millis Rosemary,
Peters Gordon,
Barnes Diana
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960422)69:2<92::aid-ijc4>3.0.co;2-q
Subject(s) - cyclin d1 , staining , immunohistochemistry , breast cancer , pathology , cancer , cyclin , mammary gland , biology , oncology , medicine , cell cycle
We have used immunohistochemical staining to assess the expression of cyclin D1 in formalin‐fixed sections of 345 breast carcinomas, dating back 20 years. Clinical follow‐up data were available on all patients. Approximately 50% of the tumours showed excessive nuclear staining for cyclin D1 as compared with normal epithelium. Some tumours showed strong cytoplasmic staining in the absence of nuclear staining, and around 25% of the tumours were judged to be negative for nuclear cyclin D1. Contrary to expectations, moderate/strong staining for cyclin D1 was associated with improved relapse‐free and overall survival relative to patients whose tumours stained weakly or negatively. Conversely, tumours that were considered negative for cyclin D1 staining had an adverse prognosis, and the poor outcome was further accentuated if the tumours were also oestrogen receptor‐negative. A possible explanation for our findings is that tumours in which cyclin D1 levels are abnormally low may have sustained mutations in other genes, such as RB 1 and that it is this abnormality that has the more significant impact on survival from breast cancer. © 1996 Wiley‐Liss, Inc.